Evidence map›Paper›PMID 41326788›Full record

ArticleBone marrow transplantation2026

Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PDWP retrospective study.

A Bertaina, M Maffeis, G Lucchini, J E Galimard, A Dalissier, K Kleinschmidt, M Ansari, M Benakli, O C Mirci-Danicar, D Pagliara and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

A Bertaina *Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3729-436X
M Maffeis *Pediatric Oncohematology and Bone Marrow Unit, Children's Hospital, ASST Spedali Civili, Brescia, Italy. marianna.maffeis@asst-spedalicivili.it.
G LucchiniPediatric Stem Cell Transplantation Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
J E GalimardEBMT Statistical Unit, Hôpital Saint-Antoine, Paris, France.ORCID 0000-0001-9102-4427
A DalissierEBMT Paris Study Unit, Hôpital Saint-Antoine, Paris, France.
K KleinschmidtDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.ORCID 0000-0002-1447-7286
M AnsariCansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva and Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland.
M BenakliPierre and Marie Curie Center, University of Health Sciences, Algiers, Algeria.ORCID 0000-0001-8444-890X
O C Mirci-DanicarPaediatric Bone Marrow Transplant Unit, Bristol Royal Hospital for Children, Bristol, UK.
D PagliaraDepartment of Hematology/Oncology, Cell and Gene Therapy, IRCSS Bambino Gesù Children's Hospitale, Rome, Italy.
J H DalleHôpital Robert Debré, Pediatric Hematology and Immunology Department, GHU AP-HP Nord Université Paris Cité, Paris, France.
A Al AhmariKing Faisal Specialist Hospital & Research Centre (Paeds), Riyadh, Saudi Arabia.ORCID 0000-0002-8732-5611
E SkorobogatovaThe Russian Federation Children's Research Hospital, Moscow, Russian Federation.
C RenardInstitut d'Hematologie et Oncologie Pediatrique, Hospices Civils de Lyon, Lyon, France.
J StyczynskiUniversity Hospital, Collegium Medicum UMK Pediatric Hematology and Oncology, Bydgoszcz, Poland.ORCID 0000-0002-3158-119X
R RihaniKing Hussein Cancer Centre, Pediatric BMT Program, Amman, Jordan.ORCID 0009-0007-4610-6272
R FormankovaDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
A BalduzziPediatric Stem Cell Transplantation Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID 0000-0002-5879-0610
C JubertCHU Bordeaux Groupe Hospitalier Pellegrin-Enfants, Bordeaux, France.
E GoussetisSt Sophia Children's hospital Oncology center, Athens, Greece.
M IfversenDept for Children and Adolescent medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-2558-1935
A LankesterWillem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-6703-2993
B VersluijsPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
M AljurfOncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.ORCID 0000-0003-3942-7370
P BaderDivision for Stem Cell Transplantation and Immunology, Department of Pediatrics, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0003-4554-0265
S CorbaciogluDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.ORCID 0000-0003-1070-8486
K KalwakDepartment of Pediatric Hematology, Oncology, and BMT, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0003-1174-5799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interplay between graft-versus-host disease (aGVHD) and the graft-versus-leukemia (GVL) effect in children with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) remains complex. This EBMT Pediatric Diseases Working Party (PDWP) retrospective analysis of 2374 pediatric AML patients evaluated the impact of aGVHD on relapse incidence (RI), non-relapse mortality (NRM), overall survival (OS), and leukemia-free survival (LFS). Grade III/IV aGVHD significantly reduced RI (HR: 0.61, p = 0.01) while significantly increasing NRM (HR: 4.51, p < 0.001), offsetting any benefits in OS and LFS. Grade II aGVHD increased NRM (HR: 2.07, p = 0.002) without affecting RI or OS, while grade I aGVHD had no significant impact on these outcomes. Patients with Grade II or higher aGVHD were at greater risk of both chronic (c)GvHD (HR: 1.98 for Grade II; HR: 4.33 for Grade III/IV, p < 0.001) and extensive cGVHD (HR: 2.52 for Grade II; HR: 4.91 for Grade III/IV, p < 0.001). These findings highlight the challenge of mitigating NRM while preserving the GVL effect to optimize disease control and long-term survival in pediatric AML. This study provides critical insights for refining post-transplant strategies in this population.

Indexed as

Graft vs Host DiseaseGraft vs Leukemia EffectHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAcute DiseaseAdolescentAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleHumansIncidenceInfantMaleRecurrence

Identifiers

PMID41326788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.